Evidence map›Paper›PMID 40175340›Full record

ArticleSignal transduction and targeted therapy2025

A donor PD-1

Dan Liu, Xue Wang, Yuheng Han, Jing Wang, Yidan Sun, Yafei Hou, Qian Wu, Cong Zeng, Xuping Ding, Yingjun Chang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dan Liu *Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xue Wang *Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuheng HanShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing WangBlood and Marrow Transplantation Center, Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yidan SunBlood and Marrow Transplantation Center, Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yafei HouShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qian WuShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cong ZengShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xuping DingShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yingjun ChangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Jiong HuBlood and Marrow Transplantation Center, Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. hj10709@rjh.com.cn.ORCID 0000-0002-5613-1195
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China. xjhrm@medmail.com.cn.ORCID 0000-0002-2145-6643
Liming LuShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. youlanda2009@sjtu.edu.cn.ORCID 0000-0002-2544-966X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81671579National Natural Science Foundation of China (National Science Foundation of China) 81930004National Natural Science Foundation of China (National Science Foundation of China) 82071856
6 · The paper itself

Abstract

Donor selection determines the occurrence of acute graft-versus-host-disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). To optimize the current clinical donor selection criteria and identify putative donor lymphocyte subsets associated with better recipient outcomes, we analyzed the peripheral CD4

Indexed as

CD8-Positive T-LymphocytesGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationMemory T CellsProgrammed Cell Death 1 ReceptorAdultAnimalsFemaleHumansMaleMiceMiddle AgedTissue DonorsT-Lymphocytes, RegulatoryGranulocyte Colony-Stimulating FactorPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID40175340
PMCPMC11965471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.